Prognostic significance of the systemic immune‐inflammation index in pancreatic carcinoma patients: a meta-analysis. Issue 8 (27th August 2021)

• Record Type: Journal Article
• Authors: Li, Xiaocheng; Lin, Huapeng; Ouyang, Renbin; Yang, Yaowei; Peng, Jing
• Is Part Of: Bioscience reports. Volume 41:Issue 8(2021)
• Publication Date: 2021-08-27
• Subjects: meta-analysis -- pancreatic carcinoma -- prognosis -- systemic immune-inflammation index; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20204401
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Background: Systemic immune-inflammation index (SII) is a prognostic indicator for several malignancies, including pancreatic carcinoma; however, there is no consensus on its significance. In the current study, a systematic meta-analysis was used to explore the correlation between SII and prognosis in pancreatic carcinoma patients. Methods: PubMed, Embase and Cochrane Library databases were screened from inception to May 2020. Studies describing the prognostic role of SII in pancreatic carcinoma were then retrieved. The pooled hazard ratio (HR) and 95% confidence interval (CI) was calculated using random- or fixed-effects models to determine the correlation between SII and prognosis. Results: A total of four studies, comprising 1749 patients, met the inclusion criteria of the study and were therefore included in this meta-analysis. The meta-analysis showed that high SII indicated was correlated with worse overall survival (OS) in patients with pancreatic carcinoma (HR: 1.43, 95% CI: 1.24–1.65, P <0.001). These findings were validated through subgroup analyses, stratified by the American Joint Committee on Cancer (AJCC) stage. In addition, patients with high SII showed poorer cancer-specific survival (HR: 2.32, 95% CI: 1.55–3.48, P <0.001). However, analysis showed no significant correlations between SII and disease-free and relapse-free survival (RFS). Conclusion: These findings indicate that SII is a potential non-invasive and a promising tool for predicting clinical outcomes of pancreatic carcinoma patients. However, the current research did not explore whether neoadjuvant therapy has an effect on the prognostic value of SII. Further studies using adequate designs and larger sample sizes are required to validate these findings.